{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:15:30Z","timestamp":1790828130409,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40262-024-01411-1","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T06:01:54Z","timestamp":1725688914000},"page":"1301-1312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-7372","authenticated-orcid":false,"given":"Francois Pierre","family":"Combes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin K. B.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohinoor","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yun","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"3","key":"1411_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"issue":"9976","key":"1411_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. The Lancet. 2015;385(9976):1447\u201359.","journal-title":"The Lancet"},{"issue":"5","key":"1411_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013;13(5):515\u201329.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1411_CR4","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","volume":"98","author":"FE Nicolini","year":"2013","unstructured":"Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, M\u00fcller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98(10):1510\u20136.","journal-title":"Haematologica"},{"issue":"24","key":"1411_CR5","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1411_CR6","first-page":"421","volume":"11","author":"LPAM Akard","year":"2013","unstructured":"Akard LPAM, Hill CE, Pinilla-Ibarz J. The, \u201cHit Hard and Hit Early\u201d Approach to the Treatment of Chronic Myeloid Leukemia: Implications of the Updated National Comprehensive Cancer Network Clinical Practice Guidelines for Routine Practice. Clin Adv Hematol Oncol. 2013;11(7):421\u201332.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"1411_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.htct.2018.11.005","volume":"41","author":"GR Bosi","year":"2019","unstructured":"Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials? Hematol Transfus Cell Ther. 2019;41(3):222\u20138.","journal-title":"Hematol Transfus Cell Ther."},{"issue":"19","key":"1411_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"6","key":"1411_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","volume":"15","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15(6):323\u201334.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1411_CR10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"1","key":"1411_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1182\/asheducation-2016.1.164","volume":"2016","author":"J Cortes","year":"2016","unstructured":"Cortes J, Kantarjian H. Chronic myeloid leukemia: sequencing of TKI therapies. Hematology Am Soc Hematol Educ Program. 2016;2016(1):164\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11 Suppl 17","key":"1411_CR12","first-page":"1","volume":"11","author":"MJ Mauro","year":"2013","unstructured":"Mauro MJ, Talpaz M, Radich JP. Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens? Clin Adv Hematol Oncol. 2013;11(11 Suppl 17):1\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"24","key":"1411_CR13","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326.","journal-title":"N Engl J Med"},{"key":"1411_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458.","journal-title":"Leuk Res"},{"issue":"18","key":"1411_CR15","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120\u201335.","journal-title":"J Med Chem"},{"issue":"7647","key":"1411_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"issue":"3","key":"1411_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617\u201326.","journal-title":"Leukemia"},{"issue":"5","key":"1411_CR18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/leu.2014.326","volume":"29","author":"AA Mian","year":"2015","unstructured":"Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, et al. PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia. 2015;29(5):1104\u201314.","journal-title":"Leukemia"},{"issue":"4","key":"1411_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clml.2012.04.002","volume":"12","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012;12(4):223\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1411_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","volume":"143","author":"J Geissler","year":"2017","unstructured":"Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, et al. Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143(7):1167\u201376.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1411_CR21","first-page":"e22","volume":"15","author":"SD Saini","year":"2009","unstructured":"Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33.","journal-title":"Am J Manag Care"},{"issue":"10","key":"1411_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet. 2022;61(10):1393\u2013403.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1411_CR23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/cpt.2699","volume":"112","author":"FP Combes","year":"2022","unstructured":"Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Exposure-efficacy analysis of asciminib in philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther. 2022;112(5):1040\u201350.","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"1411_CR24","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","volume":"18","author":"PW Manley","year":"2010","unstructured":"Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010;18(19):6977\u201386.","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"1411_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","volume":"39","author":"R Madabushi","year":"2022","unstructured":"Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res. 2022;39(8):1669\u201380.","journal-title":"Pharm Res"},{"issue":"5","key":"1411_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40262-018-0705-y","volume":"58","author":"SKB Sy","year":"2019","unstructured":"Sy SKB, Zhuang L, Sy S, Derendorf H. Clinical pharmacokinetics and pharmacodynamics of ceftazidime-avibactam combination: a model-informed strategy for its clinical development. Clin Pharmacokinet. 2019;58(5):545\u201364.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1411_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/cpt.2742","volume":"112","author":"K Venkatakrishnan","year":"2022","unstructured":"Venkatakrishnan K, van der Graaf PH. Toward project optimus for oncology precision medicine: multi-dimensional dose optimization enabled by quantitative clinical pharmacology. Clin Pharmacol Ther. 2022;112(5):927\u201332.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1411_CR28","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","volume":"38","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u2265 1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38(7):1522\u201333.","journal-title":"Leukemia"},{"issue":"11","key":"1411_CR29","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/jcph.1926","volume":"61","author":"M Hoch","year":"2021","unstructured":"Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, et al. Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharmacol. 2021;61(11):1454\u201365.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1411_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cpdd.1019","volume":"11","author":"M Hoch","year":"2022","unstructured":"Hoch M, Zack J, Quinlan M, Huth F, Forte S, Dodd S, et al. Pharmacokinetics of asciminib when taken with imatinib or with food. Clin Pharmacol Drug Dev. 2022;11(2):207\u201319.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1411_CR31","unstructured":"The Food and Drug Administration U. Highlights of asciminib prescribing information. 2021 [cited 2022 November 10]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215358s000Orig1lbl.pdf. Accessed 21 Aug 2024."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01411-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T01:06:09Z","timestamp":1727917569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01411-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01411-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"9 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Novartis Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Francois Pierre Combes (FPC), Sherwin K. B. Sy (SS), Ying Fei Li (YFL), Kohinoor Dasgupta (KD), Sebastien Lorenzo (SL), Shruti Kapoor (SK), Matthias Hoch (MH), and Yu-Yun Ho (YYH) are employees of Novartis. FPC and MH are also Novartis stockholders. FPC is also a shareholder of Simulation Plus. None of the authors declares any other conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Anonymized patient\u2010level data from clinical trials may be shared by Novartis in a consortium called ClinicalStudyDataRequest.com (CSDR) in accordance with Novartis\u2019 policy for sharing clinical trial data (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"This analysis was based on the data from patients enrolled in two different clinical trials. Both trials, serving as the data sources for this analysis, were approved by the appropriate Institutional Review Board.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All the authors contributed to conception and design of the research, data collection, analysis, and interpretation, as well as drafting, reviewing, and providing final approval of the manuscript. Conceptualization: SS, FPC, MH, SL, YFL, YYH. Formal analysis: SS, FPC, SL, YFL. Validation: SS, FPC, SL, YFL. Investigation: SS, SL, FPC, YFL. Visualization: SL, FPC, YFL. Methodology: SS, SL, FPC, YFL, YYH. Writing\u2014original draft: SS, SL, FPC, YFL. Writing\u2014review and editing: SS, FPC, YFL, SL, MH, YYH, KD, SK.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}